Current Infectious Disease Reports

, Volume 2, Issue 1, pp 25–30 | Cite as

Public health strategies to prevent genital herpes: Where do we stand?

  • H. Hunter Handsfield


At least 25% of the United States population has overt or subclinical genital herpes simplex virus (HSV) infection, and herpes probably is the sexually transmitted disease of greatest concern to sexually active persons, aside from AIDS. In addition to its direct clinical and psychosexual complications, genital herpes is an important determinant of sexual transmission of HIV. Genital herpes is usually transmitted by persons with subclinical infection, whether entirely asymptomatic or with unrecognized symptoms. Although the composition and efficacy of a national genital herpes prevention program are in debate, clinicians should adopt a public health perspective in managing patients to help prevent transmission. Specific approaches include accurate diagnosis of genital ulcer disease by routine use of virologic tests for HSV; use of type-specific serologic tests to diagnose subclinical HSV infection in patients’ sex partners and others at high risk; counseling patients to recognize symptoms and defer sex with uninfected partners when symptomatic; and serologic testing and counseling of pregnant women and their partners to prevent neonatal herpes. Antiviral chemotherapy may be effective in preventing herpes-related cesarean sections, and its efficacy in preventing sexual transmission of HSV is under study.


Genital Herpes Herpes Simplex Virus Infection Public Health Strategy Recurrent Herpes Neonatal Herpes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Corey L: Raising the consciousness for identifying and controlling viral STDs: fears and frustrations. Sex Transm Dis 1998, 25:58–69.PubMedCrossRefGoogle Scholar
  2. 2.
    Mindel A: Genital herpes: how much of a public-health problem? Lancet 1998, 351(suppl 3):16–18.PubMedCrossRefGoogle Scholar
  3. 3.
    Corey L, Handsfield HH: Genital herpes: addressing a global public health problem. JAMA 1999, in press.Google Scholar
  4. 4.
    Johnson RE, Nahmias AJ, Magder LS, et al.: A seroepidemiology survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1990, 321:8–12.Google Scholar
  5. 5.
    Fleming DT, McQuillan GM, Johnson RE, et al.: Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997, 337:1105–1111. Presentation of the results of HSV seroprevalence studies in the National Health and Nutrition Examination Survey and comparison with similar studies performed a decade earlier, showing a rise in HSV-2 seroprevalence from 16.7% in 1978 to 21.4% in 1991.PubMedCrossRefGoogle Scholar
  6. 6.
    Corey L, Wald A: Genital herpes. In Sexually Transmitted Diseases, edn 3. Edited by Holmes KK, et al. New York: McGraw Hill; 1999:285–312.Google Scholar
  7. 7.
    Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance, 1997. Atlanta: CDC, US Department of Health and Human Services; 1998:32.Google Scholar
  8. 8.
    Kaiser Family Foundation: Sexually transmitted diseases in America: how many cases and at what cost? Research Triangle Park, NC: American Social Health Assocation; 1998:1–24.Google Scholar
  9. 9.
    Mertz KJ, Trees D, Levine WC, et al.: Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. J Infect Dis 1998, 178:1795–1798. The first systematic study of the differential diagnosis of genital ulcer disease in the United States in almost two decades. Using highly sensitive PCR assays, the investigators documented the dominant role of HSV in causing genital ulcers, even in populations selected for high rates of syphilis.PubMedCrossRefGoogle Scholar
  10. 10.
    Ashley R, Cent A, Maggs V, et al.: Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991, 115:520–526.PubMedGoogle Scholar
  11. 11.
    Ashley RL: Type-specific antibodies to HSV-1 and -2: review of methodology. Herpes 1998, 5:33–38.Google Scholar
  12. 12.
    Ashley RL, Wald A: Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999, 12:1–8.PubMedGoogle Scholar
  13. 13.
    Breinig MK, Kingsley LA, Armstrong JA, et al.: Epidemiology of genital herpes in Pittsburgh: serologic, sexual and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis 1990, 162:299–305.PubMedGoogle Scholar
  14. 14.
    Wald A, Koutsky L, Ashley RL, Corey L: Genital herpes in a primary care clinic: demographic and sexual correlates of herpes simplex type 2 infections. Sex Transm Dis 1997, 24:149–155.PubMedGoogle Scholar
  15. 15.
    Langenberg A, Benedetti J, Jenkins J, et al.: Development of clinically recognizable genital lesions among women previously identified as having asymptomatic herpes simplex virus type 2 infections. Ann Intern Med 1989, 110:882–887.PubMedGoogle Scholar
  16. 16.
    Koutsky L, Stevens CE, Holmes KK, et al.: Under diagnosis of genital herpes by current clinical and viral isolation procedures. N Engl J Med 1992, 326:1533–1539.PubMedCrossRefGoogle Scholar
  17. 17.
    Wald A, Zeh J, Selke S, et al.: Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995, 333:770–775.PubMedCrossRefGoogle Scholar
  18. 18.
    Wald A, Corey L, Cone R, et al.: Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997, 99:1092–1097. One of several superior studies by the premier investigators of subclinical HSV infections, showing the high rate of subclinical viral shedding and documenting the efficacy of antiviral therapy in reducing (but not eliminating) viral shedding.PubMedCrossRefGoogle Scholar
  19. 19.
    Kulhanjian JA, Soroush BS, Au DS, et al.: Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med 1992, 326:916–920.PubMedCrossRefGoogle Scholar
  20. 20.
    Brown ZA, Selke S, Zeh J, et al.: The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997, 337:509–515. The results of a prospective study in which more than 30,000 pregnant women had routine type-specific HSV serology and viral cultures at term. The study confirmed that initial maternal herpes much more frequently results in transmission to the newborn than recurrent infection, and documented a high rate of HSV-1 as the cause of neonatal herpes.PubMedCrossRefGoogle Scholar
  21. 21.
    Roberts SW, Cox SM, Dax J, et al.: Genital herpes during pregnancy: no lesions, no cesearean. Obstet Gynecol 1995, 85:261–264.PubMedCrossRefGoogle Scholar
  22. 22.
    Fleming DT, Wasserheit JN: From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to transmission of HIV infection. Sex Transm Infect 1999, 75:3–17. A thorough and well-written review of the association of STDs with HIV transmission, including comprehensive summaries of all the important studies published to date.PubMedGoogle Scholar
  23. 23.
    Dickerson M, Johnson J, Delea TE, et al.: The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus: an application of the Bradford Hill Criteria. Sex Transm Dis 1996, 23:429–440.PubMedCrossRefGoogle Scholar
  24. 24.
    Centers for Disease Control and Prevention: HIV prevention through early detection and treatment of other sexually transmitted diseases—United States. MMWR 1998, 47(suppl RR-12):1–24.Google Scholar
  25. 25.
    Schacker T, Ryncarz AJ, Goddard J, et al.: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1 infected men. JAMA 1998, 280:61–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Schacker T, Zeh J, Hu HL, et al.: Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998, 178:1616–1622.PubMedCrossRefGoogle Scholar
  27. 27.
    Garnett GP, Anderson RM: Sexually transmitted diseases and sexual behavior: insights from mathematical models. J Infect Dis 1996, 174(suppl_2):150–161.Google Scholar
  28. 28.
    Handsfield HH, Stone KM, Wasserheit JW: Prevention agenda for genital herpes. Sex Transm Dis 1999, 26:228–231.PubMedCrossRefGoogle Scholar
  29. 29.
    Corey L, Langenberg AGM, Ashley R, et al.: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized, double-blind placebo-controlled trials. JAMA 1999, 282:331–340.PubMedCrossRefGoogle Scholar
  30. 30.
    DiCarlo RP, Martin DH: The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997, 25:292–298.PubMedGoogle Scholar
  31. 31.
    Wald A: New therapies and prevention strategies for genital herpes. Clin Infect Dis 1999, 28(suppl 1):4–13. This excellent review of genital herpes treatment and potential prevention strategies was prepared as a background paper for the Centers for Disease Control and Prevention’s 1998 Sexually Transmitted Diseases Treatment Guidelines.CrossRefGoogle Scholar
  32. 32.
    Fairley I, Monteiro EF: Patient attitudes to type specific serological tests in the diagnosis of genital herpes. Genitourinary Med 1997, 73:259–262.Google Scholar
  33. 33.
    Wald A, Zeh J, Barnum G, et al.: Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996, 124:8–15.PubMedGoogle Scholar
  34. 34.
    Blower SM, Porco TC, Darby G: Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nature Med 1998, 4:673–678.PubMedCrossRefGoogle Scholar
  35. 35.
    Scott LL, Sanchez PJ, Jackson GL, et al.: Acyclovir suppression to prevent cesearean delivery after first-episode genital herpes. Obstet Gynecol 1996, 87:69–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Scott LL: Prevention of perinatal herpes: prophylactic antiviral therapy? Clin Obstet Gynecol 1999, 42:134–148.PubMedCrossRefGoogle Scholar
  37. 37.
    Brocklehurst P, Kinghorn G, Carney O, et al.: A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998, 105:275–280.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2000

Authors and Affiliations

  • H. Hunter Handsfield
    • 1
  1. 1.Harborview Medical CenterSeattleUSA

Personalised recommendations